Tagged with Strategy

Germany DACH should become a powerhouse for the Group Germany is emerging as a key growth and launch market for Ipsen, with the DACH region now ranking as the Group’s leading European affiliate and gaining momentum across Oncology, Rare Disease and Neuroscience. As Ipsen enters its next phase of growth, new…

Germany Our objective is to navigate ongoing healthcare reforms successfully, serve as a primary growth engine for Viatris in Europe, and maximize our contribution to patient care Simon von Boeselager, Country Manager Germany at Viatris brings extensive experience across pharmaceutical strategy, commercial leadership, and digital health. He highlights Germany’s role as…

Europe ESTEVE has successfully reshaped itself in the recent years as an integrated healthcare company with two distinct growth engines: highly specialised pharmaceuticals and a global small-molecule CDMO platform, united by a shared purpose, long-term vision and a commitment to improving patients’ lives. As the US grows in relevance and investment…

Denmark Novo Nordisk has rebranded as ‘Novo’ and plans to enter new therapeutic areas as part of CEO Maziar Mike Doustdar’s push to reinvigorate growth. The company has already reinvented itself once in recent memory. Faced with flatlining sales in the late 2010s, Novo transformed from a narrow diabetes specialist into…

Europe Over three decades at Terumo, Takuya Hosogai has seen the Group evolve across businesses, markets and technologies. Now leading Terumo Europe, he discusses the region’s growing role in Pharmaceutical Solutions alongside its established interventional business, and how closer pharma partnerships, continuous innovation and a deeply rooted culture are shaping its…

USA Thomas Seewoester, Vice President Site Operations and Site Head at Amgen Manufacturing Limited, LLC, has overseen Puerto Rico’s most significant manufacturing campus for three years, building on more than three decades of Amgen presence and USD six billion in cumulative investment. Seewoester discusses the rationale behind a further USD one…

Germany We have the agility to move quickly, the expertise to navigate complex healthcare systems, and the commitment to bring innovative medicines to patients who are often overlooked Norgine is reshaping its DACH business around a new growth engine, pairing a well-established portfolio with an expanded push into rare and ultra-rare…

Germany We believe that flexibility, analytical drive, initiative, and a detailed, hands-on mindset are more important than industry experience Peter Gerckens, CEO at PharmaSGP combines a strong background in consulting, branding, and consumer healthcare with an entrepreneurial approach to pharmaceutical growth. He emphasizes data-driven decision-making, small, agile teams, and in-house capabilities…

Europe Europe accounts for a substantial share of Takeda’s business, hosts a significant slice of the company’s manufacturing footprint, and is involved in around half of its late-stage trials and priority development programmes. As the group prepares potential launches in narcolepsy, psoriasis and polycythaemia vera, a rare blood cancer, Gamze Yuceland explains how patient insight,…

Germany Tomas Mihal, General Manager for Germany at STADA, discusses the company’s diversified three-pillar model across consumer healthcare, generics and specialty medicines, highlighting its strong German market position, agile culture and five-year growth strategy. He outlines his priorities around acquisitions, digital and e-commerce expansion, selective biosimilar and innovation opportunities, supply resilience,…

Germany Growth in rare diseases is measured differently. It is not simply about launching new products, but about improving diagnosis, strengthening healthcare partnerships, and supporting patients throughout their journey. Those principles are shaping Orphalan’s next chapter, as the company expands beyond its longstanding focus on Wilson disease into new rare diseases.…

Germany Germany is the default first-choice European market for launching new, innovative medicines. But with the country’s pricing system under growing strain from both national and international pressures, some in the industry are asking how long that status can hold.   Germany is, by far, Europe’s leading country for fast and…